Hanall Biopharma (009420) — Free Cash Flow Generation Index
Hanall Biopharma (009420) has a Free Cash Flow Generation Index of 0.55x as of September 2025. Free cash flow of ₩4.07 Billion represents 1% of operating cash flow (₩7.34 Billion). Read Hanall Biopharma (009420) total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Free Cash Flow Generation Index (2011–2024)
Historical FCF Generation Index trend for Hanall Biopharma across 10 annual periods. Explore Hanall Biopharma capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Hanall Biopharma (2011–2024)
Year-by-year Free Cash Flow Generation Index for Hanall Biopharma. For the full company profile including market capitalisation, see market cap of Hanall Biopharma.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.46x | ₩-13.71 Billion | ₩9.36 Billion | ₩23.07 Billion | ▼ -312.3% |
| 2023 | 0.69x | ₩20.45 Billion | ₩29.64 Billion | ₩9.20 Billion | ▼ -0.8% |
| 2022 | 0.70x | ₩17.53 Billion | ₩25.20 Billion | ₩2.83 Billion | ▲ +107.2% |
| 2021 | -9.72x | ₩-8.16 Billion | ₩839.87 Million | ₩4.61 Billion | ▼ -39.8% |
| 2020 | -6.95x | ₩-6.46 Billion | ₩929.29 Million | ₩2.56 Billion | ▼ -1266.2% |
| 2019 | 0.60x | ₩12.22 Billion | ₩20.49 Billion | ₩2.12 Billion | ▼ -37.1% |
| 2017 | 0.95x | ₩39.93 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -53.1% |
| 2016 | 2.02x | ₩7.98 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +1.3% |
| 2012 | 1.99x | ₩4.38 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +88.6% |
| 2011 | 1.06x | ₩7.84 Billion | ₩7.41 Billion | ₩426.70 Million | — |